CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.
P/B ratio for CTI BioPharma Corp. (CTIC)
P/B ratio as of 2022: -39.22
According to CTI BioPharma Corp.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is -39.22. At the end of 2021 the company had a P/B ratio of 59.33.
P/B ratio history for CTI BioPharma Corp. from 1996 to 2022
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2022 | -39.22 |
| 2021 | 59.33 |
| 2020 | 5.72 |
| 2019 | 5.11 |
| 2018 | 0.70 |
| 2017 | 4.48 |
| 2016 | 8.55 |
| 2015 | 6.63 |
| 2014 | 8.39 |
| 2013 | 4.83 |
| 2012 | 2.19 |
| 2011 | 6.93 |
| 2010 | -52.65 |
| 2009 | -28.15 |
| 2008 | -0.03 |
| 2007 | -0.79 |
| 2006 | -1.93 |
| 2005 | -1.31 |
| 2004 | -6.22 |
| 2003 | -3.51 |
| 2002 | 5.64 |
| 2001 | 7.45 |
| 2000 | 6.42 |
| 1999 | 5.20 |
| 1998 | 0.98 |
| 1997 | 3.64 |
| 1996 | 4.45 |